19.28
price down icon1.78%   -0.35
after-market Handel nachbörslich: 19.25 -0.03 -0.16%
loading
Schlusskurs vom Vortag:
$19.63
Offen:
$19.7
24-Stunden-Volumen:
410.43K
Relative Volume:
0.48
Marktkapitalisierung:
$227.05M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-121.02M
KGV:
-1.7123
EPS:
-11.26
Netto-Cashflow:
$-114.09M
1W Leistung:
-1.83%
1M Leistung:
+8.80%
6M Leistung:
-44.18%
1J Leistung:
-15.77%
1-Tages-Spanne:
Value
$19.10
$20.56
1-Wochen-Bereich:
Value
$18.59
$20.56
52-Wochen-Spanne:
Value
$7.31
$130.00

Tonix Pharmaceuticals Holding Corp Stock (TNXP) Company Profile

Name
Firmenname
Tonix Pharmaceuticals Holding Corp
Name
Telefon
212-980-9155
Name
Adresse
26 MAIN STREET, SUITE 101, CHATHAM, NY
Name
Mitarbeiter
81
Name
Twitter
@TONIXPharma
Name
Nächster Verdiensttermin
2025-03-17
Name
Neueste SEC-Einreichungen
Name
TNXP's Discussions on Twitter

Vergleichen Sie TNXP mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
TNXP
Tonix Pharmaceuticals Holding Corp
19.28 231.17M 0 -121.02M -114.09M -11.26
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
452.04 113.14B 11.74B 3.68B 3.34B 14.19
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
741.29 78.49B 14.25B 4.58B 3.88B 41.77
Biotechnology icon
ARGX
Argen X Se Adr
877.94 54.76B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
397.55 54.51B 3.21B 43.57M 221.36M 0.2405
Biotechnology icon
INSM
Insmed Inc
197.01 41.64B 447.02M -1.18B -906.14M -6.1812

Tonix Pharmaceuticals Holding Corp Stock (TNXP) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2022-04-18 Eingeleitet Noble Capital Markets Outperform
2019-04-18 Hochstufung ROTH Capital Neutral → Buy
2017-08-18 Hochstufung ROTH Capital Neutral → Buy
2016-09-07 Herabstufung ROTH Capital Buy → Neutral
2016-02-17 Bestätigt Oppenheimer Outperform
2015-11-04 Eingeleitet Cantor Fitzgerald Buy
2015-06-12 Eingeleitet Oppenheimer Outperform
2015-02-17 Bestätigt ROTH Capital Buy
2014-09-29 Bestätigt ROTH Capital Buy
Alle ansehen

Tonix Pharmaceuticals Holding Corp Aktie (TNXP) Neueste Nachrichten

pulisher
Dec 11, 2025

Equities Analysts Offer Predictions for TNXP FY2025 Earnings - MarketBeat

Dec 11, 2025
pulisher
Dec 10, 2025

Tonix Pharmaceuticals Appoints Irina Ishak as General Counsel Amid Key Commercialization Phase - citybuzz

Dec 10, 2025
pulisher
Dec 09, 2025

Tonix Pharmaceuticals Appoints Irina Ishak as General Counsel - citybiz

Dec 09, 2025
pulisher
Dec 08, 2025

TNXP: Tonix Now a Commercial Stage Company Following the Launch of Tonmya - Smartkarma

Dec 08, 2025
pulisher
Dec 08, 2025

TNXP: Tonix Now a Commercial Stage Company Following the Launch of Tonmya™ - Yahoo Finance

Dec 08, 2025
pulisher
Dec 07, 2025

TNXP Stock Today, 7 December 2025: Price, Latest News and 2026 Forecasts for Tonix Pharmaceuticals - ts2.tech

Dec 07, 2025
pulisher
Dec 04, 2025

Is Tonix Pharmaceuticals Holding Corp. stock ready for breakout - Newser

Dec 04, 2025
pulisher
Dec 03, 2025

Tonix receives FDA clearance to launch phase 2 trial for major depressive disorder - Proactive financial news

Dec 03, 2025
pulisher
Dec 03, 2025

Is Tonix Pharmaceuticals Holding Corp. stock positioned well for digital economy2025 Buyback Activity & Stepwise Entry and Exit Trade Signals - Newser

Dec 03, 2025
pulisher
Dec 02, 2025

Tonix reports positive results in TNX-1500 phase 1 trial - MSN

Dec 02, 2025
pulisher
Dec 01, 2025

Tonix Pharmaceuticals (TNXP) Stock Analysis Report | Ratings, Financials & Performance - Benzinga

Dec 01, 2025
pulisher
Dec 01, 2025

Will Tonix Pharmaceuticals Holding (NASDAQ:TNXP) Spend Its Cash Wisely? - Sahm

Dec 01, 2025
pulisher
Nov 28, 2025

Aug Drivers: Why Tonix Pharmaceuticals Holding Corp. stock is trending among retail traders2025 Price Targets & Weekly Watchlist for Hot Stocks - moha.gov.vn

Nov 28, 2025
pulisher
Nov 27, 2025

Why analysts remain bullish on Tonix Pharmaceuticals Holding Corp. stockCPI Data & Daily Volume Surge Signals - moha.gov.vn

Nov 27, 2025
pulisher
Nov 27, 2025

Tonix Pharmaceuticals Stock Jumps Into Retail Spotlight After $25M Buyback Boost — Traders See ‘Blueprint For Rerating’ - MSN

Nov 27, 2025
pulisher
Nov 26, 2025

What drives Tonix Pharmaceuticals Holding Corp stock priceTake Profit Strategies & Free Daily Top Stock Picks for All Investors - earlytimes.in

Nov 26, 2025
pulisher
Nov 24, 2025

Tonix: Maintaining Buy Rating With Potential Tonmya Expansion Indications (NASDAQ:TNXP) - Seeking Alpha

Nov 24, 2025
pulisher
Nov 24, 2025

Tonix Pharmaceuticals launches TONMYA, a first-in-class non-opioid Fibromyalgia therapy - Proactive financial news

Nov 24, 2025
pulisher
Nov 24, 2025

FDA clears IND for Tonix’s depression treatment candidate By Investing.com - Investing.com Nigeria

Nov 24, 2025
pulisher
Nov 24, 2025

Tonix Pharma’s IND Clearance Boosts MDD Treatment Efforts - TipRanks

Nov 24, 2025
pulisher
Nov 24, 2025

Tonix Pharmaceuticals (TNXP) Secures FDA Clearance for Depressio - GuruFocus

Nov 24, 2025
pulisher
Nov 24, 2025

Tonix To Initiate Phase 2 Trial Of TNX-102 SL For Major Depressive Disorder In Mid-2026 - RTTNews

Nov 24, 2025
pulisher
Nov 24, 2025

Tonix Pharmaceuticals gets FDA clearance to develop TNX-102 for depression - Seeking Alpha

Nov 24, 2025
pulisher
Nov 24, 2025

Tonix Pharmaceuticals announces FDA IND clearance for phase 2 study of TNX-102 SL - MarketScreener

Nov 24, 2025
pulisher
Nov 24, 2025

Tonix Pharmaceuticals Announces FDA Ind Clearance For Phase 2 Study Of Tnx-102 Sl - TradingView

Nov 24, 2025
pulisher
Nov 24, 2025

Pharmaceuticals Receives FDA Clearance to Proceed With Phase 2 Study of TNX-102 SL for Major Depressive Disorder - MarketScreener

Nov 24, 2025
pulisher
Nov 24, 2025

Tonix Pharmaceuticals (TNXP) Advances with FDA IND Clearance for Depression Treatment - GuruFocus

Nov 24, 2025
pulisher
Nov 24, 2025

FDA clears IND for Tonix’s depression treatment candidate - Investing.com India

Nov 24, 2025
pulisher
Nov 24, 2025

Tonix Pharmaceuticals Announces FDA IND Clearance for Phase 2 Study of TNX-102 SL for the Treatment of Major Depressive Disorder - The Manila Times

Nov 24, 2025
pulisher
Nov 24, 2025

Tonix Pharmaceuticals to Advance TNX-102 SL into Pivotal Phase 2 Study for Major Depressive Disorder Following IND Clearance from FDA - Quiver Quantitative

Nov 24, 2025
pulisher
Nov 24, 2025

Tonix Pharma (Nasdaq: TNXP) cleared to start Phase 2 HORIZON MDD study of TNX-102 SL - Stock Titan

Nov 24, 2025
pulisher
Nov 21, 2025

Tonix Pharmaceuticals increases stock offering capacity to $400 million By Investing.com - Investing.com Nigeria

Nov 21, 2025
pulisher
Nov 21, 2025

Tonix Pharmaceuticals increases stock offering capacity to $400 million - Investing.com

Nov 21, 2025
pulisher
Nov 21, 2025

Tonix Pharma Amends Sales Agreement to Raise Capital - TipRanks

Nov 21, 2025
pulisher
Nov 21, 2025

Tonix Pharmaceuticals amends sales agreement with Alliance Global PartnersSEC filing - MarketScreener

Nov 21, 2025
pulisher
Nov 21, 2025

Will Tonix Pharmaceuticals Holding Corp. stock split again soonEarnings Recap Report & Expert Approved Momentum Trade Ideas - newser.com

Nov 21, 2025
pulisher
Nov 20, 2025

Can Tonix Pharmaceuticals Holding Corp. stock resist market sell offs2025 Big Picture & Long-Term Capital Growth Ideas - newser.com

Nov 20, 2025
pulisher
Nov 20, 2025

How Tonix Pharmaceuticals Holding Corp. stock responds to policy changesCEO Change & Short-Term High Return Ideas - newser.com

Nov 20, 2025
pulisher
Nov 19, 2025

Risk vs reward if holding onto Tonix Pharmaceuticals Holding Corp.Entry Point & Step-by-Step Swing Trade Plans - newser.com

Nov 19, 2025
pulisher
Nov 19, 2025

Will Tonix Pharmaceuticals Holding Corp. stock deliver shareholder valueOil Prices & Consistent Growth Equity Picks - newser.com

Nov 19, 2025
pulisher
Nov 19, 2025

Tonix Pharmaceuticals Holding Corp. (TNXP) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade

Nov 19, 2025
pulisher
Nov 18, 2025

Tonix Pharma Expands Share Repurchase Program - TipRanks

Nov 18, 2025
pulisher
Nov 18, 2025

Tonix Pharmaceuticalsincreases share repurchase program to $35 millionSEC filing - MarketScreener

Nov 18, 2025
pulisher
Nov 18, 2025

[8-K] Tonix Pharmaceuticals Holding Corp. Reports Material Event | TNXP SEC FilingForm 8-K - Stock Titan

Nov 18, 2025
pulisher
Nov 18, 2025

Tonix Pharmaceuticals Expands Share Repurchase Program - TradingView

Nov 18, 2025
pulisher
Nov 18, 2025

Real time alert setup for Tonix Pharmaceuticals Holding Corp. performance2025 Volatility Report & Safe Capital Growth Stock Tips - newser.com

Nov 18, 2025

Finanzdaten der Tonix Pharmaceuticals Holding Corp-Aktie (TNXP)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$38.39
price down icon 1.08%
$95.41
price down icon 0.72%
$31.31
price down icon 3.07%
$94.81
price down icon 1.24%
biotechnology ONC
$319.06
price down icon 0.55%
$197.01
price up icon 0.91%
Kapitalisierung:     |  Volumen (24h):